α-Amanitin

α-Amanitin (''alpha''-Amanitin) is a cyclic peptide of eight amino acids. It is possibly the most deadly of all the amatoxins, toxins found in several species of the mushroom genus ''Amanita'', one being the death cap (''Amanita phalloides'') as well as the destroying angel, a complex of similar species, principally '' A. virosa'' and '' A. bisporigera''. It is also found in the mushrooms '' Galerina marginata'', '' Lepiota subincarnata'' and '' Conocybe filaris''. The oral of amanitin is 100 Î¼g/kg for rats.

Unlike most cyclic peptides, amatoxins (and phallotoxins) are synthesized on ribosomes. The genes encoding the proprotein for α-amanitin belong to the same family as those that encode for phallacidin (a phallotoxin).

Scientific use

α-Amanitin is a selective inhibitor of RNA polymerase II and III but not I. This mechanism makes it a deadly toxin.

α-Amanitin can also be used to determine which types of RNA polymerase are present. This is done by testing the sensitivity of the polymerase in the presence of α-amanitin. RNA polymerase I is insensitive, RNA polymerase II is highly sensitive (inhibited at 1μg/ml), RNA polymerase III is moderately sensitive (inhibited at 10μg/ml), and RNA polymerase IV is slightly sensitive (inhibited at 50μg/ml).

Chemical structure

α-Amanitin is a highly modified bicyclic octapeptide consisting of an outer and an inner loop. The outer loop is formed by peptide bonds between a carboxyl terminus of an amino acid to the subsequent amino terminus of the next residue. The inner loop is closed by a tryptathionine linkage between 6-hydroxy-tryptophan and cysteine. In addition, α-amanitin is decorated with modified amino acid side chains (2''S'',3''R'',4''R'')-4,5-dihydroxy-isoleucine, ''trans''-4-hydroxy-proline, which gives its high affinity for RNA polymerase II and III.

Detection techniques

Early methods to detect alpha-amanitin included thin-layer chromatography (TLC). In most solvent systems used in TLC, alpha-amanitin and beta-amanitin would travel at different rates, thus allowing individual identification of each toxin. Another early method was the Meixner test (also known as the Wieland test), which would detect amatoxins, but also yielded false positives for some compounds, such as psilocin. Capillary zone electrophoresis was also developed, but was not adequately sensitive for clinical samples, but sufficient for mushroom extracts.

More recently, the use of high-performance liquid chromatography (HPLC) has become the preferred method, which allows for better resolution, reproducibility, and higher sensitivity. A range of detectors can be paired with HPLC, such as UV or mass spectrometry.

As early as the 1980s, antibody-based assays (immunoassays) were developed for amanitin (but more often recognize amatoxins as the antibodies cross-react with some of the congeners). The earliest immunoassays were radioimmunoassays and then enzyme linked immunosorbent assays (ELISAs). More, recently, in 2020, a monoclonal antibody-based lateral flow immunoassay (similar to a pregnancy test) has been developed that can quickly and selectively detect amatoxins in mushrooms and in urine samples.

Total synthesis

Matinkhoo et al. devised strategies to surmount three synthetic hurdles to give α-amanitin in 2018. First, enantioselective synthesis of solid phase peptide synthesis-compatible (2''S'',3''R'',4''R'')-4,5-dihydroxyisoleucine was afforded in 11 steps from 2-(benzyloxy)acetaldehyde. Two key stereochemistry-defining steps include Brown crotylation at (''3R'',''4R'')-positions, and asymmetric Strecker amino acid synthesis at the (''2S'')- α carbon. Secondly, chemoselective inner ring closure by fluorocyclization between 6-hydroxytrytophan and cysteine was achieved by intra-annular Savige-Fontana reaction. This requires a solid phase peptide synthesis-compatible, and methyliminodiacetic acid (MIDA), a boron protecting group, orthogonal amino acid in 5 steps. As a final step, enantioselective oxidation at the tryptathionine linkage was achieved using a bulky organic oxidizing agent and an optimized solvent system to afford the desired bio-reactive (''R'')-enantiomer sulfoxide, completing the total synthesis.

Symptoms of poisoning

α-Amanitin has an unusually strong and specific attraction to the enzyme RNA polymerase II. Upon ingestion and uptake by liver cells, it binds to the RNA polymerase II enzyme, effectively causing cytolysis of hepatocytes (liver cells). Few effects are reported within 10 hours; it is not unusual for significant effects to take as long as 24 hours after ingestion to appear, with this delay in symptoms making α-amanitin poisoning even more difficult to diagnose and all the more dangerous. By then, it is far past the time in which stomach pumping would yield an efficient result. Diarrhea and cramps are the first symptoms, but those pass, giving a false sign of remission. Typically, on the 4th to 5th day, the toxin starts to have severe effects on the liver and kidneys, leading to total system failure in both. Death usually takes place around a week from ingestion.

Around 15% of those poisoned will die within 10 days, progressing through a comatose stage to kidney failure, liver failure, hepatic coma, respiratory failure and death. Those who recover are at risk of permanent liver damage. Diagnosis is difficult, and is established by observation of the clinical symptoms as well as the presence of α-amanitin in the urine. Urine screening is generally most useful within 48 hours of ingestion. Treatment is mainly supportive (gastric lavage, activated carbon, fluid resuscitation) but includes various drugs to counter the amatoxins, including intravenous penicillin and cephalosporin derivatives, and, in cases of greater ingestion, can extend to an orthotopic liver transplant. The most reliable method to treat amanitin poisoning is through gastric lavage immediately after ingestion; however, the onset of symptoms is generally too late for this to be an option. Chemically modified silibinin, silibinin dihydrogen disuccinate disodium (trade name Legalon SIL) a solution for IV administration, is used in treatment of severe intoxications with hepatotoxic substances such as paracetamol and amanitins.

Mode of inhibitory action

Based on a 2002 crystal structure analysis, α-amanitin interacts with the bridge helix in RNA polymerase II (pol II). This interaction interferes with the translocation of RNA and DNA needed to empty the site for the next round of RNA synthesis. The addition of α-amanitin can reduce the rate of pol II translocating on DNA from several thousand to a few nucleotides per minute, but has little effect on the affinity of pol II for nucleoside triphosphate, and a phosphodiester bond can still be formed. The bridge helix has evolved to be flexible and its movement is required for translocation of the polymerase along the DNA backbone. Binding of α-amanitin puts a constraint on its mobility, hence slowing down the translocation of the polymerase and the rate of synthesis of the RNA molecule.

Use in antibody-drug conjugates

A new antibody-drug conjugate (ADC) technology based on α-amanitin has shown activity in therapy-resistant tumor cells, e.g. cells expressing multi-drug resistant transporters, tumor-initiating cells and non-dividing cells at picomolar concentrations.

The unique mode of action of α-amanitin seems to make the amanitin-based ADCs a suitable toxic payload. Amanitin has a water-soluble structure, resulting in ADCs with low tendency for aggregation.

See also

* Mushroom poisoning
* Antibody-drug conjugate

References

External links

Heidelberg Pharma, GmbH

{{DEFAULTSORT:Amanitin, alpha-

Cyclic peptides
Amatoxins
Hepatotoxins
Enzyme inhibitors
RNA polymerase inhibitors
Sulfoxides
Experimental cancer drugs
Octapeptides